Shouyao Holdings: RET inhibitor Sotorasib tablets (SY-5007) new drug application has been accepted
I'm PortAI, I can summarize articles.
Shouyao Holdings announced that its self-developed RET inhibitor Sotorasib tablets (SY-5007) have been accepted for new drug application by the National Medical Products Administration. This drug is suitable for patients with locally advanced or metastatic non-small cell lung cancer with RET gene fusion positivity, showing significant efficacy and good safety, and is expected to provide new treatment options for patients
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments